Hyderabad News Top Stories

Biological E’s PNEUBEVAX 14 gains WHO nod for global use

Vaccine offers broad serotype coverage and strong immunity

Hyderabad: PNEUBEVAX 14 Wins WHO Pre Qualification as Biological E. Limited announced that the World Health Organisation has granted pre-qualification status to its 14-valent Pneumococcal Conjugate Vaccine. The Hyderabad-based company said the vaccine, known as P NEUBEVAX 14® or BE-PCV-14, h as now become its 11th WHO pre-qualified product. The approval marks an important step in improving access to pneumococcal vaccines for global immunisation programmes.

Here To Join Us On WhatsApp

The company said PNEUBEVAX 14® protects i nfants against 14 Streptococcus pneumoniae serotypes. These include serotypes 22F and 33F, which are not

See Full Page